Compounds with growth hormone releasing properties
申请人:Novo Nordisk A/S
公开号:US06083908A1
公开(公告)日:2000-07-04
Compounds of Formula I ##STR1## and their use for treating medical disorders resulting from a deficiency in growth hormone are disclosed, wherein R.sup.1, R.sup.2, R.sup.3a, R.sup.4a, R.sup.5a, G, J and D are as defined in the specification.
A series of GH secretagogues based on modifications in the C-terminal of NN703 is reported. The C-terminal N-methyl amide of NN703 has been replaced with alkylated hydrazides in order to decrease the volume of distribution and identify GH secretagogues with shorter duration of action. Most of the prepared compounds show high potency in a rat pituitary assay. Subsequent to an initial in vivo screening in dogs, four compounds were selected for further pharmacological and pharmacokinetic evaluation. The four compounds showed oral bioavailability around 35% and equipotency in vitro compared to NN703. The relationship between lipophilicity and volume of distribution is discussed and it is speculated whether the lower volume of distribution is attributed to the observed higher in vivo potency and shorter plasma elimination half-life. (C) 2000 Editions scientifiques et medicales Elsevier SAS.
Use of Polyanions for Alkylation of Hydrazine Derivatives
作者:Aleksei Bredihhin、Uno Mäeorg
DOI:10.1021/ol702234s
日期:2007.11.1
Alkylation of hydrazine and its derivatives still remains a quite complicated task. The novel method utilizing the polyanion strategy is reported. Formation and use of trianion for alkylation of hydrazine derivatives is first reported. Described method provides fast and convenient access to multialkylated derivatives. Scope and limitations of new method are also investigated.